Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 7 8 7

+8 more TTM periods

ROE
21.97% 21.62% 27.97% 39.69%
ROA
13.78% 12.54% 14.48% 17.46%
ROIC
42.61% 51.10% 43.78% 39.95%
Return on Tangible Assets
28.02% 29.50% 38.12% 60.46%
Average Days of Receivables
53.76 42.30 85.75 57.79
Free Cash Flow per Share
0.81 1.05 0.83 0.85
Free Cash Flow
41.15 53.61 41.73 42.87
Other line items

Show all line items

Columns are period end dates